Neuromyelitis optica spectrum disorder after treatment with pembrolizumab
| Autor: | Kazumasa Yokoyama, Tomoyo Shimada, Nobutaka Hattori, Emi Nakagawa, Anri Hattori, Yasunobu Hoshino, Taiji Tsunemi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Neuromyelitis optica
biology business.industry medicine.drug_class Multiple sclerosis General Medicine Pembrolizumab medicine.disease Monoclonal antibody Immune checkpoint 03 medical and health sciences 0302 clinical medicine Immune system Neurology Cancer research biology.protein Medicine 030212 general & internal medicine Neurology (clinical) Antibody business 030217 neurology & neurosurgery Brain metastasis |
| Zdroj: | Multiple Sclerosis and Related Disorders. 37:101447 |
| ISSN: | 2211-0348 |
| DOI: | 10.1016/j.msard.2019.101447 |
| Popis: | While immune checkpoint inhibitors (ICIs) have contributed to the development of therapeutic treatments for previously incurable advanced malignancies, they may induce immune-related adverse events (irAEs) in many organs including the CNS [1]. Because immune checkpoint molecules are predominantly expressed on T cells, irAEs are largely not B cell-mediated. Here, we report a patient who was treated with pembrolizumab (a PD-1 monoclonal antibody) for lung adenocarcinoma with brain metastasis, and who developed anti-aquaporin-4 antibody (AQP4-Ab) positive neuromyelitis optica spectrum disorder (NMOSD). We hypothesized that PD-1 immune checkpoint blockage might induce a B cell-mediated immune response in CNS resulting in this complication, which was further supported by the observation of a transient increase in plasmablasts in their CSF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect